Faculty of Medicine
Library of the School of Health Sciences

2020-10-26

2020

Chatzirallis Alexandros

Χρυσάνθη Κουτσανδρέα, Καθηγήτρια Οφθαλμολογίας, Τμήμα Ιατρικής, ΕΚΠΑ
Παναγιώτης Θεοδοσιάδης, Καθηγητής Οφθαλμολογίας, Τμήμα Ιατρικής, ΕΚΠΑ
Ευαγγελία-Μαρία Μόσχου, Αναπληρώτρια Καθηγήτρια Οφθαλμολογίας, Τμήμα Ιατρικής, ΕΚΠΑ
Κλειώ Χατζηστεφάνου, Αναπληρώτρια Καθηγήτρια Οφθαλμολογίας, Τμήμα Ιατρικής, ΕΚΠΑ
Αθανάσιος Ράπτης, Αναπληρωτής Καθηγητής Παθολογίας-Σακχαρώδους Διαβήτη, Τμήμα Ιατρικής, ΕΚΠΑ
Χρήστος Κρούπης, Αναπληρωτής Καθηγητής Κλινικής Βιοχημείας-Ιατρικής Χημείας, Τμήμα Ιατρικής, ΕΚΠΑ
Κωνσταντίνος Δρούτσας, Επίκουρος Καθηγητής Οφθαλμολογίας, Τμήμα Ιατρικής, ΕΚΠΑ

Πολυμεταβλητή ανάλυση αποτελεσματικότητας αντι-αγγειογενετικών παραγόντων στο διαβητικό οίδημα της ωχράς κηλίδας

Greek

Multivariate analysis of anti-vascular endothelial growth factor agents efficacy in diabetic macular edema

Purpose: The purpose of this study was to compare the anatomical and functional outcomes of ranibizumab versus aflibercept for the treatment of diabetic macular edema (DME) in a long-term follow-up.
Methods: Participants in this prospective study were 112 treatment naïve patients with DME, who received treatment with either intravitreal ranibizumab (n=54) or aflibercept (n=58). The demographic data, the best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography (SD-OCT) characteristics were evaluated at baseline and at month 1,2,3,6,12 and 18 post treatment, while factors affecting visual outcome were determined using multivariate analysis.
Results: At month 18, the mean BCVA of ranibizumab-treated eyes increased 7.9 letters compared to 6.9 letters for eyes receiving aflibercept, with greater number of injections in ranibizumab group (9.2±2.3 vs. 7.6±2.1 injections in the ranibizumab and aflibercept group respectively, p=0.0002). The difference in letters between the two groups was not statistically significant, nor the difference in central subfield thickness at month 18. Factors associated with poorer BCVA were found to be increasing age, HbA1c ≥7.5%, increasing central retinal thickness and disrupted ellipsoid zone.
Conclusions: Ranibizumab and aflibercept presented similar anatomical and functional outcomes in 18-month follow-up in patients with DME. It is important to determine factors, affecting VA, so as to provide individualized treatment.

Health Sciences

Diabetes mellitus, macular edema, ranibizumab, aflibercept, treatment, prognosis

No

0

Yes

74

93

File access is restricted only to the intranet of UoA.

https://pergamos.lib.uoa.gr/uoa/dl/object/2926332